Physician profile
John E Liljenquist
NPI 1619977600
$480.41
in general payments reported to CMS, 2019-2025
11 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $55.96 · 2021: $32.27 · 2023: $38.58 · 2024: $51.93 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $144.63 | 2019-2025 | Tepezza |
| Novo Nordisk INC | $78.16 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.82 | 2019-2024 | Synjardy, Jardiance |
| Tandem Diabetes Care, INC. | $44.89 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $40.67 | 2019 | |
| Lilly USA, LLC | $32.03 | 2019-2023 | Mounjaro |
| Medtronic Minimed, INC. | $25.12 | 2019 | |
| Radius Health, INC. | $18.01 | 2023 | Tymlos |
| Boston Scientific Corporation | $14.01 | 2025 | General - Pain Management |
| Abbott Laboratories | $11.07 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Liljenquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.